<SEC-DOCUMENT>0001591986-20-000007.txt : 20200214
<SEC-HEADER>0001591986-20-000007.hdr.sgml : 20200214
<ACCEPTANCE-DATETIME>20200214162632
ACCESSION NUMBER:		0001591986-20-000007
CONFORMED SUBMISSION TYPE:	13F-HR
PUBLIC DOCUMENT COUNT:		2
CONFORMED PERIOD OF REPORT:	20191231
FILED AS OF DATE:		20200214
DATE AS OF CHANGE:		20200214
EFFECTIVENESS DATE:		20200214

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Aquilo Capital Management, LLC
		CENTRAL INDEX KEY:			0001591986
		IRS NUMBER:				272448001
		STATE OF INCORPORATION:			CA
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		13F-HR
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	028-18892
		FILM NUMBER:		20620576

	BUSINESS ADDRESS:	
		STREET 1:		ONE LETTERMAN DRIVE
		STREET 2:		SUITE D4900, BUILDING D
		CITY:			SAN FRANCISCO
		STATE:			CA
		ZIP:			94129
		BUSINESS PHONE:		415-635-0140

	MAIL ADDRESS:	
		STREET 1:		ONE LETTERMAN DRIVE
		STREET 2:		SUITE D4900, BUILDING D
		CITY:			SAN FRANCISCO
		STATE:			CA
		ZIP:			94129

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Aquilo Capital Managment, LLC
		DATE OF NAME CHANGE:	20131114
</SEC-HEADER>
<DOCUMENT>
<TYPE>13F-HR
<SEQUENCE>1
<FILENAME>primary_doc.xml
<TEXT>
<XML>
<?xml version="1.0" encoding="UTF-8"?>
<edgarSubmission xmlns="http://www.sec.gov/edgar/thirteenffiler" xmlns:com="http://www.sec.gov/edgar/common">
  <headerData>
    <submissionType>13F-HR</submissionType>
    <filerInfo>
      <liveTestFlag>LIVE</liveTestFlag>
      <flags>
        <confirmingCopyFlag>false</confirmingCopyFlag>
        <returnCopyFlag>false</returnCopyFlag>
        <overrideInternetFlag>false</overrideInternetFlag>
      </flags>
      <filer>
        <credentials>
          <cik>0001591986</cik>
          <ccc>XXXXXXXX</ccc>
        </credentials>
      </filer>
      <periodOfReport>12-31-2019</periodOfReport>
    </filerInfo>
  </headerData>
  <formData>
    <coverPage>
      <reportCalendarOrQuarter>12-31-2019</reportCalendarOrQuarter>
      <filingManager>
        <name>Aquilo Capital Management, LLC</name>
        <address>
          <com:street1>ONE LETTERMAN DRIVE</com:street1>
          <com:street2>SUITE D4900, BUILDING D</com:street2>
          <com:city>SAN FRANCISCO</com:city>
          <com:stateOrCountry>CA</com:stateOrCountry>
          <com:zipCode>94129</com:zipCode>
        </address>
      </filingManager>
      <reportType>13F HOLDINGS REPORT</reportType>
      <form13FFileNumber>028-18892</form13FFileNumber>
      <provideInfoForInstruction5>N</provideInfoForInstruction5>
    </coverPage>
    <signatureBlock>
      <name>Howard Nurtman</name>
      <title>Compliance Consultant</title>
      <phone>310.806.6267</phone>
      <signature>Howard Nurtman</signature>
      <city>Beverly Hills</city>
      <stateOrCountry>CA</stateOrCountry>
      <signatureDate>02-14-2020</signatureDate>
    </signatureBlock>
    <summaryPage>
      <otherIncludedManagersCount>0</otherIncludedManagersCount>
      <tableEntryTotal>12</tableEntryTotal>
      <tableValueTotal>266237</tableValueTotal>
      <isConfidentialOmitted>false</isConfidentialOmitted>
    </summaryPage>
  </formData>
</edgarSubmission>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>INFORMATION TABLE
<SEQUENCE>2
<FILENAME>Q42019_13F.xml
<TEXT>
<XML>
<?xml version="1.0" encoding="UTF-8" standalone="yes"?>
<ns1:informationTable xmlns:ns1="http://www.sec.gov/edgar/document/thirteenf/informationtable">
	<ns1:infoTable>
		<ns1:nameOfIssuer>DICERNA PHARMACEUTICALS INC </ns1:nameOfIssuer>
		<ns1:titleOfClass>COM</ns1:titleOfClass>
		<ns1:cusip>253031108</ns1:cusip>
		<ns1:value>13536</ns1:value>
		<ns1:shrsOrPrnAmt>
			<ns1:sshPrnamt>614436</ns1:sshPrnamt>
			<ns1:sshPrnamtType>SH</ns1:sshPrnamtType>
		</ns1:shrsOrPrnAmt>
		<ns1:investmentDiscretion>SOLE</ns1:investmentDiscretion>
		<ns1:votingAuthority>
			<ns1:Sole>614436</ns1:Sole>
			<ns1:Shared>0</ns1:Shared>
			<ns1:None>0</ns1:None>
		</ns1:votingAuthority>
	</ns1:infoTable>
	<ns1:infoTable>
		<ns1:nameOfIssuer>FATE THERAPEUTICS INC </ns1:nameOfIssuer>
		<ns1:titleOfClass>COM</ns1:titleOfClass>
		<ns1:cusip>31189P102</ns1:cusip>
		<ns1:value>1414</ns1:value>
		<ns1:shrsOrPrnAmt>
			<ns1:sshPrnamt>72273</ns1:sshPrnamt>
			<ns1:sshPrnamtType>SH</ns1:sshPrnamtType>
		</ns1:shrsOrPrnAmt>
		<ns1:investmentDiscretion>SOLE</ns1:investmentDiscretion>
		<ns1:votingAuthority>
			<ns1:Sole>72273</ns1:Sole>
			<ns1:Shared>0</ns1:Shared>
			<ns1:None>0</ns1:None>
		</ns1:votingAuthority>
	</ns1:infoTable>
	<ns1:infoTable>
		<ns1:nameOfIssuer>GALAPAGOS NV </ns1:nameOfIssuer>
		<ns1:titleOfClass>SPON ADR</ns1:titleOfClass>
		<ns1:cusip>36315X101</ns1:cusip>
		<ns1:value>14885</ns1:value>
		<ns1:shrsOrPrnAmt>
			<ns1:sshPrnamt>71967</ns1:sshPrnamt>
			<ns1:sshPrnamtType>SH</ns1:sshPrnamtType>
		</ns1:shrsOrPrnAmt>
		<ns1:investmentDiscretion>SOLE</ns1:investmentDiscretion>
		<ns1:votingAuthority>
			<ns1:Sole>71967</ns1:Sole>
			<ns1:Shared>0</ns1:Shared>
			<ns1:None>0</ns1:None>
		</ns1:votingAuthority>
	</ns1:infoTable>
	<ns1:infoTable>
		<ns1:nameOfIssuer>MERUS N V </ns1:nameOfIssuer>
		<ns1:titleOfClass>COM</ns1:titleOfClass>
		<ns1:cusip>N5749R100</ns1:cusip>
		<ns1:value>14626</ns1:value>
		<ns1:shrsOrPrnAmt>
			<ns1:sshPrnamt>1038746</ns1:sshPrnamt>
			<ns1:sshPrnamtType>SH</ns1:sshPrnamtType>
		</ns1:shrsOrPrnAmt>
		<ns1:investmentDiscretion>SOLE</ns1:investmentDiscretion>
		<ns1:votingAuthority>
			<ns1:Sole>1038746</ns1:Sole>
			<ns1:Shared>0</ns1:Shared>
			<ns1:None>0</ns1:None>
		</ns1:votingAuthority>
	</ns1:infoTable>
	<ns1:infoTable>
		<ns1:nameOfIssuer>MORPHOSYS AG </ns1:nameOfIssuer>
		<ns1:titleOfClass>SPONSORED ADS</ns1:titleOfClass>
		<ns1:cusip>617760202</ns1:cusip>
		<ns1:value>217</ns1:value>
		<ns1:shrsOrPrnAmt>
			<ns1:sshPrnamt>6080</ns1:sshPrnamt>
			<ns1:sshPrnamtType>SH</ns1:sshPrnamtType>
		</ns1:shrsOrPrnAmt>
		<ns1:investmentDiscretion>SOLE</ns1:investmentDiscretion>
		<ns1:votingAuthority>
			<ns1:Sole>6080</ns1:Sole>
			<ns1:Shared>0</ns1:Shared>
			<ns1:None>0</ns1:None>
		</ns1:votingAuthority>
	</ns1:infoTable>
	<ns1:infoTable>
		<ns1:nameOfIssuer>PIERIS PHARMACEUTICALS INC </ns1:nameOfIssuer>
		<ns1:titleOfClass>COM</ns1:titleOfClass>
		<ns1:cusip>720795103</ns1:cusip>
		<ns1:value>17769</ns1:value>
		<ns1:shrsOrPrnAmt>
			<ns1:sshPrnamt>4966820</ns1:sshPrnamt>
			<ns1:sshPrnamtType>SH</ns1:sshPrnamtType>
		</ns1:shrsOrPrnAmt>
		<ns1:investmentDiscretion>SOLE</ns1:investmentDiscretion>
		<ns1:votingAuthority>
			<ns1:Sole>4966820</ns1:Sole>
			<ns1:Shared>0</ns1:Shared>
			<ns1:None>0</ns1:None>
		</ns1:votingAuthority>
	</ns1:infoTable>
	<ns1:infoTable>
		<ns1:nameOfIssuer>PROQR THRAPEUTICS N V </ns1:nameOfIssuer>
		<ns1:titleOfClass>SHS EURO</ns1:titleOfClass>
		<ns1:cusip>N71542109</ns1:cusip>
		<ns1:value>19053</ns1:value>
		<ns1:shrsOrPrnAmt>
			<ns1:sshPrnamt>1922570</ns1:sshPrnamt>
			<ns1:sshPrnamtType>SH</ns1:sshPrnamtType>
		</ns1:shrsOrPrnAmt>
		<ns1:investmentDiscretion>SOLE</ns1:investmentDiscretion>
		<ns1:votingAuthority>
			<ns1:Sole>1922570</ns1:Sole>
			<ns1:Shared>0</ns1:Shared>
			<ns1:None>0</ns1:None>
		</ns1:votingAuthority>
	</ns1:infoTable>
	<ns1:infoTable>
		<ns1:nameOfIssuer>REGENXBIO INC </ns1:nameOfIssuer>
		<ns1:titleOfClass>COM</ns1:titleOfClass>
		<ns1:cusip>75901B107</ns1:cusip>
		<ns1:value>11012</ns1:value>
		<ns1:shrsOrPrnAmt>
			<ns1:sshPrnamt>268778</ns1:sshPrnamt>
			<ns1:sshPrnamtType>SH</ns1:sshPrnamtType>
		</ns1:shrsOrPrnAmt>
		<ns1:investmentDiscretion>SOLE</ns1:investmentDiscretion>
		<ns1:votingAuthority>
			<ns1:Sole>268778</ns1:Sole>
			<ns1:Shared>0</ns1:Shared>
			<ns1:None>0</ns1:None>
		</ns1:votingAuthority>
	</ns1:infoTable>
	<ns1:infoTable>
		<ns1:nameOfIssuer>SPDR SERIES TRUST </ns1:nameOfIssuer>
		<ns1:titleOfClass>S&amp;P BIOTECH</ns1:titleOfClass>
		<ns1:cusip>78464A870</ns1:cusip>
		<ns1:value>118888</ns1:value>
		<ns1:shrsOrPrnAmt>
			<ns1:sshPrnamt>1250000</ns1:sshPrnamt>
			<ns1:sshPrnamtType>SH</ns1:sshPrnamtType>
		</ns1:shrsOrPrnAmt>
		<ns1:putCall>Put</ns1:putCall>
		<ns1:investmentDiscretion>SOLE</ns1:investmentDiscretion>
		<ns1:votingAuthority>
			<ns1:Sole>0</ns1:Sole>
			<ns1:Shared>0</ns1:Shared>
			<ns1:None>1250000</ns1:None>
		</ns1:votingAuthority>
	</ns1:infoTable>
	<ns1:infoTable>
		<ns1:nameOfIssuer>SPERO THERAPEUTICS INC </ns1:nameOfIssuer>
		<ns1:titleOfClass>COM</ns1:titleOfClass>
		<ns1:cusip>84833T103</ns1:cusip>
		<ns1:value>11099</ns1:value>
		<ns1:shrsOrPrnAmt>
			<ns1:sshPrnamt>1154356</ns1:sshPrnamt>
			<ns1:sshPrnamtType>SH</ns1:sshPrnamtType>
		</ns1:shrsOrPrnAmt>
		<ns1:investmentDiscretion>SOLE</ns1:investmentDiscretion>
		<ns1:votingAuthority>
			<ns1:Sole>1154356</ns1:Sole>
			<ns1:Shared>0</ns1:Shared>
			<ns1:None>0</ns1:None>
		</ns1:votingAuthority>
	</ns1:infoTable>
	<ns1:infoTable>
		<ns1:nameOfIssuer>UNIQURE NV </ns1:nameOfIssuer>
		<ns1:titleOfClass>SHS</ns1:titleOfClass>
		<ns1:cusip>N90064101</ns1:cusip>
		<ns1:value>28442</ns1:value>
		<ns1:shrsOrPrnAmt>
			<ns1:sshPrnamt>396899</ns1:sshPrnamt>
			<ns1:sshPrnamtType>SH</ns1:sshPrnamtType>
		</ns1:shrsOrPrnAmt>
		<ns1:investmentDiscretion>SOLE</ns1:investmentDiscretion>
		<ns1:votingAuthority>
			<ns1:Sole>396899</ns1:Sole>
			<ns1:Shared>0</ns1:Shared>
			<ns1:None>0</ns1:None>
		</ns1:votingAuthority>
	</ns1:infoTable>
	<ns1:infoTable>
		<ns1:nameOfIssuer>XENON PHARMACEUTICALS INC </ns1:nameOfIssuer>
		<ns1:titleOfClass>COM</ns1:titleOfClass>
		<ns1:cusip>98420N105</ns1:cusip>
		<ns1:value>15296</ns1:value>
		<ns1:shrsOrPrnAmt>
			<ns1:sshPrnamt>1166736</ns1:sshPrnamt>
			<ns1:sshPrnamtType>SH</ns1:sshPrnamtType>
		</ns1:shrsOrPrnAmt>
		<ns1:investmentDiscretion>SOLE</ns1:investmentDiscretion>
		<ns1:votingAuthority>
			<ns1:Sole>1166736</ns1:Sole>
			<ns1:Shared>0</ns1:Shared>
			<ns1:None>0</ns1:None>
		</ns1:votingAuthority>
	</ns1:infoTable>
</ns1:informationTable>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
